ImmunoGenesis announces that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference.
Read morePress releases

ImmunoGenesis CEO James Barlow to Present on Company’s Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers at BIO CEO & Investor Conference
February 9, 2022
ImmunoGenesis announces that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference.
Read more
ImmunoGenesis CEO James Barlow to Present on Company’s Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers at Biotech Showcase
January 4, 2022
ImmunoGenesis announces that CEO James Barlow will present about the company and its multiple immune-oncology therapeutic development programs at Biotech Showcase 2022 on January 10 at 2:30 PM PST.
Read more
ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers
December 14, 2021
ImmunoGenesis announced the appointment of seasoned industry veteran Charles Schweizer, PhD, as Senior Vice President of Clinical Development. Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations.
Read more
Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference
November 15, 2021
ImmunoGenesis announces that preclinical data from its lead development programs were presented in six scientific posters at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021).
Read more
Data from ImmunoGenesis’ Lead Programs to be Presented at Society for Immunotherapy of Cancer (SITC) Conference
November 3, 2021
ImmunoGenesis announces the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021).
Read more
ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals
September 1, 2021
•STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
•Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
•Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory
July 28, 2021
ImmunoGenesis announces the appointment of seasoned industry veterans to key roles to support the expansion of the company’s R&D, clinical and business development activities. ImmunoGenesis also announces the opening of a research laboratory in JLABS @ TMC to facilitate critical translational research for its drug development programs.
Read more
ImmunoGenesis Announces Publication of Phase 1 Data on its Hypoxia-Reversal Agent Highlighting Efficacy and Genetic Expression Correlatives in Advanced Cancer
June 16, 2021
Data reported in Clinical Cancer Research support the efficacy of evofosfamide in combination with checkpoint inhibition in advanced, immunologically “cold” tumors.
Read more
Acquisition Strengthens “Cold” Tumor Targeting Pipeline
December 8, 2020
• ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.
• Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer.